Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007000523) EPIGENETIC AND GENETIC TREATMENT METHOD AND SYSTEM
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/000523 International Application No.: PCT/FR2006/050413
Publication Date: 04.01.2007 International Filing Date: 04.05.2006
IPC:
C12N 5/16 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12
Fused cells, e.g. hybridomas
16
Animal cells
Applicants:
ZACOUTO, Fred [FR/FR]; FR
Inventors:
ZACOUTO, Fred; FR
Agent:
CAPRI; 33 rue de Naples F-75008 Paris, FR
Priority Data:
055118004.05.2005FR
055305807.10.2005FR
055353321.11.2005FR
Title (EN) EPIGENETIC AND GENETIC TREATMENT METHOD AND SYSTEM
(FR) SYSTEME ET PROCEDE DE TRAITEMENT GENETIQUE ET EPIGENETIQUE
Abstract:
(EN) The invention relates to an epigenetic and genetic treatment method and system. The invention can be used to rejuvenate an adult cell nucleus without passing through an embryonic stage and to obtain a tissue that is genetically-rejuvenated and autologous in relation to the original nucleus, comprising the temporary introduction of a nucleus into an enucleated oocyte (genetic rejuvenation), followed by oocyte extraction prior to cell division. The treated nucleus can then be introduced into an adult cytoplasm originating from the nucleus. In this way, cell divisions from the rejuvenated nucleus take place in an adult autologous cytoplasm and the resulting cells immediately take the form of adult, differentiated and functional cells. The rejuvenated autologous tissue thus created can then be grafted without rejection to the adult tissue of the organism from the treated nucleus. Throughout the inventive procedure, the treated cytoplasms and nuclei remain permanently in the adult state and no artificial cell differentiation is necessary. In this way, the invention is different from standard deep cloning in which the treated cells must return to the embryonic stage and which involves artificial cell differentiation. In addition, the tissues derived from standard cloning are not immunologically compatible with the original adult tissues from the treated nucleus since the cell division thereof takes place in the oocyte which represents a foreign cytoplasm to the nucleus. Moreover, standard cloning enables the creation of whole organisms unlike the inventive method and system which can only be used to treat a single tissue. The possible applications of the invention include, for example, the repair of necrotic tissues, such as a myocardial infarction, and damaged tissues, such as the retina (RMD), heart failure, renal failure, liver failure and osteoporosis, the treatment of cancers that occur with age, such as prostate cancer, rectal cancer, colon cancer, etc. The anodyne implantation of a small volume of autologous, rejuvenated, still-healthy cells from the affected organ should inhibit the aforementioned cancers and the metastases thereof.
(FR) L'invention permet notamment de rajeunir un noyau cellulaire adulte sans passer par un stade embryonnaire et d'obtenir un tissu génétiquement rajeuni et autologue par rapport au noyau d'origine. Ceci peut être réalisé par l'introduction temporaire d'un noyau dans un ovocyte énuclée (rajeunissement génétique) suivit de son extraction ovocytaire avant sa division cellulaire. Le noyau traité peut ensuite être introduit dans un cytoplasme adulte originaire du noyau. Ainsi les divisions cellulaires à partir de ce noyau rajeuni se feront dans un cytoplasme autologue et adulte et les cellules qui en résultent seront immédiatement adultes, différentiées et fonctionnelles. Le tissu autologue rajeuni ainsi crée pourra être greffé sans rejet au niveau du tissu adulte de l'organisme de provenance du noyau traité. Au cours de la procédure de l'invention, les noyaux et cytoplasmes traités restent constamment à l'état adulte et aucune différentiation cellulaire artificielle n'est nécessaire. L'invention se différencie donc du clonage classique total qui exige un retour à l'état embryonnaire des cellules traitées et une différentiation cellulaire artificielle. En outre les tissus qui dérivent du clonage classique ne sont pas immunologiquement compatibles avec les tissus adultes d'origine du noyau traité car sa division cellulaire a eu lieu dans l'ovocyte qui est un cytoplasme étranger au noyau. En outre le clonage classique permet la création d'organismes entiers contrairement à l'invention qui ne permet de traiter qu'un seul et unique tissu. Les possibilités de l'invention comprennent, par exemple, la réparation de tissus nécrosés, tel qu'un infarctus du myocarde, et de tissus lésés, tels que la rétine (DMLA), l'insuffisance cardiaque, rénale, hépatique et l'ostéoporose, le traitement des cancers survenants avec l'âge tels que ceux de la prostate, du rectum, colon, etc. L'implantation anodine d'un petit volume de cellules encore saines, rajeunis et autologues de l'organe atteint devrait permettre d'inhiber ces cancers avec leurs métastases.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: French (FR)
Filing Language: French (FR)
Also published as:
IL186988EP1885846CA2606292AU2006263797IN9110/DELNP/2007